PHVS
Pharvaris N.V.Figures below are compared against other companies classified under Pharmaceutical Preparations.
Grades vs. industry
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | Not reported | 70.7% | — |
Operating margin Operating income as a share of revenue. | Not reported | -15.3% | — |
Net margin Net income as a share of revenue. | Not reported | -13.0% | — |
Free cash flow margin Free cash flow as a share of revenue. | Not reported | -2.0% | — |
Return on equity Net income divided by shareholder equity. | -64.8% | -14.2% | — |
Return on assets Net income divided by total assets. | -58.3% | -9.5% | — |
Return on invested capital After-tax operating profit over debt plus equity less cash. | Not reported | -6.1% | — |
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Nothing here is ranked: this company reported an operating loss several times its revenue, so it is left out of its industry’s comparisons and does not count toward the medians shown. Its own figures are exactly as filed.
Insider activity
Trades reported by officers, directors and 10% shareholders on SEC Form 4. None of the last 40 reported transactions were open-market purchases — grants, option exercises and sales make up the majority of insider filings at most companies.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 12, 2026 | Lu Peng President | Withheld for tax | 117 | $31.10 | $3.6K |
| Oct 11, 2026 | Lu Peng President | Withheld for tax | 109 | $31.10 | $3.4K |
| Sep 23, 2026 | Monges Viviane Director | Open-market sale | 11,969 | $33.05 | $395.5K |
| Sep 23, 2026 | Monges Viviane Director | Option exercise | 11,969 | $8.05 | $96.4K |
| Sep 23, 2026 | Monges Viviane Director | Option exercise(derivative) | 11,969 | $0.00 | $0.00 |
| Sep 22, 2026 | Lu Peng President | Option exercise | 45,308 | $2.59 | $117.3K |
| Sep 22, 2026 | Schikan Johannes Gerardus Christiaan Petrus Director | Open-market sale | 800 | $36.19 | $29.0K |
| Sep 22, 2026 | Schikan Johannes Gerardus Christiaan Petrus Director | Option exercise | 800 | $20.00 | $16.0K |
| Sep 22, 2026 | Schikan Johannes Gerardus Christiaan Petrus Director | Option exercise(derivative) | 800 | $0.00 | $0.00 |
| Sep 22, 2026 | Lu Peng President | Option exercise(derivative) | 45,308 | $0.00 | $0.00 |
| Sep 21, 2026 | Nassif David W. CFO / CLO | Open-market sale | 6,000 | $36.47 | $218.8K |
| Sep 21, 2026 | Nassif David W. CFO / CLO | Gift | 500 | $0.00 | $0.00 |
| Sep 17, 2026 | Modig Berndt Chief Executive Officer | Option exercise | 300,000 | $35.00 | $10.50M |
| Sep 17, 2026 | Schikan Johannes Gerardus Christiaan Petrus Director | Open-market sale | 200,000 | $35.00 | $7.00M |
| Sep 17, 2026 | Lu Peng President | Open-market sale | 100,000 | $35.00 | $3.50M |
| Sep 17, 2026 | Bjork Elisabeth Director | Open-market sale | 52,500 | $37.89 | $1.99M |
| Sep 17, 2026 | Lesage Anne Chief Early Development | Open-market sale | 20,000 | $38.27 | $765.5K |
| Sep 17, 2026 | Glassman Robert Director | Open-market sale | 14,493 | $38.56 | $558.8K |
| Sep 17, 2026 | Bjork Elisabeth Director | Option exercise | 35,000 | $14.39 | $503.6K |
| Sep 17, 2026 | Bjork Elisabeth Director | Option exercise | 17,500 | $18.14 | $317.4K |
| Sep 17, 2026 | Glassman Robert Director | Option exercise | 14,493 | $18.14 | $262.9K |
| Sep 17, 2026 | Lu Peng President | Option exercise | 100,000 | $2.59 | $259.0K |
| Sep 17, 2026 | Bjork Elisabeth Director | Option exercise(derivative) | 17,500 | $0.00 | $0.00 |
| Sep 17, 2026 | Bjork Elisabeth Director | Option exercise(derivative) | 35,000 | $0.00 | $0.00 |
| Sep 17, 2026 | Glassman Robert Director | Option exercise(derivative) | 14,493 | $0.00 | $0.00 |
A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.
Annual financials
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -€173.71M | -€132.40M | -€99.83M | -€75.65M | -€42.66M | -€26.07M | -€8.03M | -€4.31M |
| Net income | -€175.70M | -€134.22M | -€100.88M | -€76.33M | -€42.73M | -€25.99M | -€8.03M | -€4.31M |
| EPS (diluted) | -€2.97 | -€2.48 | -€2.63 | -€2.27 | -€1.40 | — | — | — |
| Operating cash flow | -€137.07M | -€120.13M | -€93.05M | -€67.16M | -€44.60M | -€21.50M | -€6.68M | -€3.92M |
| Capital expenditure | €164.6K | €538.1K | €90.0K | €124.3K | €130.0K | €43.0K | €13.5K | €0.00 |
| Free cash flow | -€137.24M | -€120.67M | -€93.14M | -€67.29M | -€44.73M | -€21.54M | -€6.69M | -€3.92M |
| Total assets | €301.45M | €291.37M | €398.69M | €167.73M | €212.09M | €101.10M | €20.60M | — |
| Shareholder equity | €271.27M | €267.76M | €384.05M | €149.26M | €204.95M | €95.79M | €18.67M | €4.95M |
| Cash | €291.68M | €280.73M | €391.23M | €161.84M | €209.35M | €98.63M | €20.33M | €5.39M |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
Amounts are in EUR, as the company reports them. Nothing here is converted to dollars, so these figures cannot be compared directly against a company reporting in another currency. Margins, returns and other ratios are unaffected.
Source
Figures come from Pharvaris N.V.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 20-F filed Apr 2, 2026. View filings on EDGAR.